Search Results - "FRY, Terry"

Mechanisms of resistance to CAR T cell therapy by Shah, Nirali N., Fry, Terry J.

“…The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving patients with pre-B cell acute lymphoblastic leukaemia…”
Get full text

Harnessing the biology of IL-7 for therapeutic application by Mackall, Crystal L, Fry, Terry J, Gress, Ronald E

“…Key Points Interleukin-7 (IL-7) is required for T cell development in mice and humans and is produced by stromal tissues rather than activated lymphocytes…”
Get full text

Challenges and opportunities of allogeneic donor-derived CAR T cells by Yang, Yinmeng, Jacoby, Elad, Fry, Terry J

“…PURPOSE OF REVIEWAs T cells engineered with chimeric antigen receptors (CARs) are entering advanced phases of clinical trial testing with promising results,…”
Get full text

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial by Lee, Daniel W, MD, Kochenderfer, James N, MD, Stetler-Stevenson, Maryalice, MD, Cui, Yongzhi K, MD, Delbrook, Cindy, RN, Feldman, Steven A, PhD, Fry, Terry J, MD, Orentas, Rimas, PhD, Sabatino, Marianna, MD, Shah, Nirali N, MD, Steinberg, Seth M, PhD, Stroncek, Dave, MD, Tschernia, Nick, BS, Yuan, Constance, MD, Zhang, Hua, PhD, Zhang, Ling, PhD, Rosenberg, Steven A, Prof, Wayne, Alan S, Prof, Mackall, Crystal L, Dr

“…Summary Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic…”
Get full text

Introduction: Immunological Reviews volume 290 by Fry, Terry J.

Get full text

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies by Sabatino, Marianna, Hu, Jinhui, Sommariva, Michele, Gautam, Sanjivan, Fellowes, Vicki, Hocker, James D., Dougherty, Sean, Qin, Haiying, Klebanoff, Christopher A., Fry, Terry J., Gress, Ronald E., Kochenderfer, James N., Stroncek, David F., Ji, Yun, Gattinoni, Luca

“…Long-lived, self-renewing, multipotent T memory stem cells (TSCM) can trigger profound and sustained tumor regression but their rareness poses a major hurdle…”
Get full text

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL by Shah, Nirali N, Lee, Daniel W, Yates, Bonnie, Yuan, Constance M, Shalabi, Haneen, Martin, Staci, Wolters, Pamela L, Steinberg, Seth M, Baker, Eva H, Delbrook, Cindy P, Stetler-Stevenson, Maryalice, Fry, Terry J, Stroncek, David F, Mackall, Crystal L

“…CD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia…”
Get full text

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy by Fry, Terry J, Shah, Nirali N, Orentas, Rimas J, Stetler-Stevenson, Maryalice, Yuan, Constance M, Ramakrishna, Sneha, Wolters, Pamela, Martin, Staci, Delbrook, Cindy, Yates, Bonnie, Shalabi, Haneen, Fountaine, Thomas J, Shern, Jack F, Majzner, Robbie G, Stroncek, David F, Sabatino, Marianna, Feng, Yang, Dimitrov, Dimiter S, Zhang, Ling, Nguyen, Sang, Qin, Haiying, Dropulic, Boro, Lee, Daniel W, Mackall, Crystal L

“…Fry et al . report the first results from a human trial of a CD22-directed chimeric antigen receptor (CAR) T cell therapy providing evidence of efficacy in the…”
Get full text

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors by Long, Adrienne H, Haso, Waleed M, Shern, Jack F, Wanhainen, Kelsey M, Murgai, Meera, Ingaramo, Maria, Smith, Jillian P, Walker, Alec J, Kohler, M Eric, Venkateshwara, Vikas R, Kaplan, Rosandra N, Patterson, George H, Fry, Terry J, Orentas, Rimas J, Mackall, Crystal L

“…Crystal Mackall and colleagues report that antigen-independent signaling of chimeric antigen receptors (CARs) causes T cell exhaustion and reduced therapeutic…”
Get full text

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial by Shah, Nirali N, Highfill, Steven L, Shalabi, Haneen, Yates, Bonnie, Jin, Jianjian, Wolters, Pamela L, Ombrello, Amanda, Steinberg, Seth M, Martin, Staci, Delbrook, Cindy, Hoffman, Leah, Little, Lauren, Ponduri, Anusha, Qin, Haiying, Qureshi, Haris, Dulau-Florea, Alina, Salem, Dalia, Wang, Hao-Wei, Yuan, Constance, Stetler-Stevenson, Maryalice, Panch, Sandhya, Tran, Minh, Mackall, Crystal L, Stroncek, David F, Fry, Terry J

“…Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment…”
Get full text

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity by Jacoby, Elad, Nguyen, Sang M., Fountaine, Thomas J., Welp, Kathryn, Gryder, Berkley, Qin, Haiying, Yang, Yinmeng, Chien, Christopher D., Seif, Alix E., Lei, Haiyan, Song, Young K., Khan, Javed, Lee, Daniel W., Mackall, Crystal L., Gardner, Rebecca A., Jensen, Michael C., Shern, Jack F., Fry, Terry J.

“…Adoptive immunotherapy using chimeric antigen receptor (CAR) expressing T cells targeting the CD19 B lineage receptor has demonstrated marked success in…”
Get full text

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase by Walker, Alec J., Majzner, Robbie G., Zhang, Ling, Wanhainen, Kelsey, Long, Adrienne H., Nguyen, Sang M., Lopomo, Paola, Vigny, Marc, Fry, Terry J., Orentas, Rimas J., Mackall, Crystal L.

“…We explored the utility of targeting anaplastic lymphoma kinase (ALK), a cell surface receptor overexpressed on pediatric solid tumors, using chimeric antigen…”
Get full text

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance by Yang, Yinmeng, Kohler, M Eric, Chien, Christopher D, Sauter, Christopher T, Jacoby, Elad, Yan, Chunhua, Hu, Ying, Wanhainen, Kelsey, Qin, Haiying, Fry, Terry J

“…Chimeric antigen receptor (CAR)-expressing T cells induce durable remissions in patients with relapsed/refractory B cell malignancies. CARs are synthetic…”
Get more information

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell by Ruella, Marco, Xu, Jun, Barrett, David M., Fraietta, Joseph A., Reich, Tyler J., Ambrose, David E., Klichinsky, Michael, Shestova, Olga, Patel, Prachi R., Kulikovskaya, Irina, Nazimuddin, Farzana, Bhoj, Vijay G., Orlando, Elena J., Fry, Terry J., Bitter, Hans, Maude, Shannon L., Levine, Bruce L., Nobles, Christopher L., Bushman, Frederic D., Young, Regina M., Scholler, John, Gill, Saar I., June, Carl H., Grupp, Stephan A., Lacey, Simon F., Melenhorst, J. Joseph

“…We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19 – leukemia that aberrantly expressed the anti-CD19 CAR. The…”
Get full text

Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma by Shalabi, Haneen, Kraft, Ira L, Wang, Hao-Wei, Yuan, Constance M, Yates, Bonnie, Delbrook, Cindy, Zimbelman, Julie D, Giller, Roger, Stetler-Stevenson, Maryalice, Jaffe, Elaine S, Lee, Daniel W, Shern, Jack F, Fry, Terry J, Shah, Nirali N

Get full text

The CD19neg needle in the haystack by Shah, Nirali N, Fry, Terry J

Get full text

Immune-based therapies for childhood cancer by Mackall, Crystal L., Merchant, Melinda S., Fry, Terry J.

“…Key Points Graft-versus-leukaemic effects improve survival following allogeneic stem cell transplantation for childhood leukaemia, and provide…”
Get full text

Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence by Ramakrishna, Sneha, Highfill, Steven L, Walsh, Zachary, Nguyen, Sang M, Lei, Haiyan, Shern, Jack F, Qin, Haiying, Kraft, Ira L, Stetler-Stevenson, Maryalice, Yuan, Constance M, Hwang, Jennifer D, Feng, Yang, Zhu, Zhongyu, Dimitrov, Dimiter, Shah, Nirali N, Fry, Terry J

“…Chimeric antigen receptor T-cell (CART) therapy targeting CD22 induces remission in 70% of patients with relapsed/refractory acute lymphoblastic leukemia…”
Get full text

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD by Jacoby, Elad, Yang, Yinmeng, Qin, Haiying, Chien, Christopher D., Kochenderfer, James N., Fry, Terry J.

“…Acute lymphoblastic leukemia (ALL) persisting or relapsing following bone marrow transplantation (BMT) has a dismal prognosis. Success with chimeric antigen…”
Get full text

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells by Lichtenstein, Daniel A., Schischlik, Fiorella, Shao, Lipei, Steinberg, Seth M., Yates, Bonnie, Wang, Hao-Wei, Wang, Yanyu, Inglefield, Jon, Dulau-Florea, Alina, Ceppi, Francesco, Hermida, Leandro C., Stringaris, Kate, Dunham, Kim, Homan, Philip, Jailwala, Parthav, Mirazee, Justin, Robinson, Welles, Chisholm, Karen M., Yuan, Constance, Stetler-Stevenson, Maryalice, Ombrello, Amanda K., Jin, Jianjian, Fry, Terry J., Taylor, Naomi, Highfill, Steven L., Jin, Ping, Gardner, Rebecca A., Shalabi, Haneen, Ruppin, Eytan, Stroncek, David F., Shah, Nirali N.

“…Chimeric antigen receptor (CAR) T-cell toxicities resembling hemophagocytic lymphohistiocytosis (HLH) occur in a subset of patients with cytokine release…”
Get full text